Pfizer's Phase 3 CIFFREO study for Duchenne muscular dystrophy failed, causing shares to fall.
Pfizer's shares fell after a Phase 3 CIFFREO study failed to meet its primary endpoint of improving motor function in young boys with Duchenne muscular dystrophy. The company will continue monitoring participants and reevaluate next steps for its DMD program, following a recent trial pause due to a serious adverse event. Shares were down 0.43% at $27.54 premarket.
June 13, 2024
3 Articles